Published in Clin Cancer Res on July 03, 2012
A review of mixed-effects models of tumor growth and effects of anticancer drug treatment used in population analysis. CPT Pharmacometrics Syst Pharmacol (2014) 1.30
Classical mathematical models for description and prediction of experimental tumor growth. PLoS Comput Biol (2014) 1.27
Population pharmacokinetic-pharmacodynamic modelling in oncology: a tool for predicting clinical response. Br J Clin Pharmacol (2015) 1.07
Population Pharmacokinetic/Pharmacodynamic Modeling of Tumor Size Dynamics in Pembrolizumab-Treated Advanced Melanoma. CPT Pharmacometrics Syst Pharmacol (2016) 0.98
White paper: landscape on technical and conceptual requirements and competence framework in drug/disease modeling and simulation. CPT Pharmacometrics Syst Pharmacol (2013) 0.94
Preclinical Modeling of Tumor Growth and Angiogenesis Inhibition to Describe Pazopanib Clinical Effects in Renal Cell Carcinoma. CPT Pharmacometrics Syst Pharmacol (2015) 0.77
A mathematical model of pre-diagnostic glioma growth. J Theor Biol (2015) 0.76
Modeling of non-small cell lung cancer volume changes during CT-based image guided radiotherapy: patterns observed and clinical implications. Comput Math Methods Med (2013) 0.75
Increasing the Time Interval between PCV Chemotherapy Cycles as a Strategy to Improve Duration of Response in Low-Grade Gliomas: Results from a Model-Based Clinical Trial Simulation. Comput Math Methods Med (2015) 0.75
Prediction of Response to Temozolomide in Low-Grade Glioma Patients Based on Tumor Size Dynamics and Genetic Characteristics. CPT Pharmacometrics Syst Pharmacol (2015) 0.75
A mathematical model of tumor growth and its response to single irradiation. Theor Biol Med Model (2016) 0.75
A Review of Modeling Approaches to Predict Drug Response in Clinical Oncology. Yonsei Med J (2017) 0.75
Modeling Longitudinal Preclinical Tumor Size Data to Identify Transient Dynamics in Tumor Response to Antiangiogenic Drugs. CPT Pharmacometrics Syst Pharmacol (2016) 0.75
Non-standard radiotherapy fractionations delay the time to malignant transformation of low-grade gliomas. PLoS One (2017) 0.75
In Vitro Radiosensitizing Effects of Temozolomide on U87MG Cell Lines of Human Glioblastoma Multiforme. Iran J Med Sci (2017) 0.75
Genome-wide association study identifies five susceptibility loci for glioma. Nat Genet (2009) 7.62
Radiotherapy for glioblastoma in the elderly. N Engl J Med (2007) 5.64
Isocitrate dehydrogenase 1 codon 132 mutation is an important prognostic biomarker in gliomas. J Clin Oncol (2009) 5.06
Adjuvant procarbazine, lomustine, and vincristine chemotherapy in newly diagnosed anaplastic oligodendroglioma: long-term follow-up of EORTC brain tumor group study 26951. J Clin Oncol (2012) 4.70
2011 update of the drug resistance mutations in HIV-1. Top Antivir Med (2011) 3.66
Update of the drug resistance mutations in HIV-1: March 2013. Top Antivir Med (2013) 3.58
A new alternative mechanism in glioblastoma vascularization: tubular vasculogenic mimicry. Brain (2010) 3.53
IDH1 and IDH2 mutations are prognostic but not predictive for outcome in anaplastic oligodendroglial tumors: a report of the European Organization for Research and Treatment of Cancer Brain Tumor Group. Clin Cancer Res (2010) 3.13
Primary brain tumours in adults. Lancet (2003) 3.05
Spontaneous and therapeutic prognostic factors in adult hemispheric World Health Organization Grade II gliomas: a series of 1097 cases: clinical article. J Neurosurg (2013) 2.98
Mutations associated with failure of raltegravir treatment affect integrase sensitivity to the inhibitor in vitro. Antimicrob Agents Chemother (2008) 2.61
Aquaporin-4 antibody-negative neuromyelitis optica: distinct assay sensitivity-dependent entity. Neurology (2013) 2.59
Continuous growth of mean tumor diameter in a subset of grade II gliomas. Ann Neurol (2003) 2.43
Disrupted surface cross-talk between NMDA and Ephrin-B2 receptors in anti-NMDA encephalitis. Brain (2012) 2.39
Clinical specificities of adult male patients with NMDA receptor antibodies encephalitis. Neurology (2014) 2.38
Primary brain tumours in adults. Lancet (2012) 2.37
Clinically validated genotype analysis: guiding principles and statistical concerns. Antivir Ther (2004) 2.14
Interactions between atazanavir-ritonavir and tenofovir in heavily pretreated human immunodeficiency virus-infected patients. Antimicrob Agents Chemother (2004) 2.14
Progressive multifocal leukoencephalopathy in patients with sarcoidosis. Neurology (2014) 2.13
The G140S mutation in HIV integrases from raltegravir-resistant patients rescues catalytic defect due to the resistance Q148H mutation. Nucleic Acids Res (2009) 2.00
Skull-base metastases. J Neurooncol (2005) 2.00
Leptomeningeal metastases from solid malignancy: a review. J Neurooncol (2005) 1.94
MRI monitoring of neuroinflammation in mouse focal ischemia. Stroke (2006) 1.91
Chromosome 7p11.2 (EGFR) variation influences glioma risk. Hum Mol Genet (2011) 1.83
Glutamatergic pre-ictal discharges emerge at the transition to seizure in human epilepsy. Nat Neurosci (2011) 1.76
Anaplastic oligodendrogliomas with 1p19q codeletion have a proneural gene expression profile. Mol Cancer (2008) 1.72
Health-related quality of life in patients treated for anaplastic oligodendroglioma with adjuvant chemotherapy: results of a European Organisation for Research and Treatment of Cancer randomized clinical trial. J Clin Oncol (2007) 1.72
Identification of regions correlating MGMT promoter methylation and gene expression in glioblastomas. Neuro Oncol (2009) 1.68
BAC array CGH distinguishes mutually exclusive alterations that define clinicogenetic subtypes of gliomas. Int J Cancer (2008) 1.66
Efficacy of a twice-daily antiretroviral regimen containing 100 mg ritonavir/400 mg indinavir in HIV-infected patients. AIDS (2003) 1.64
Safety and efficacy of adefovir dipivoxil in patients infected with lamivudine-resistant hepatitis B and HIV-1. J Hepatol (2005) 1.63
Optimal use of maraviroc in clinical practice. AIDS (2008) 1.60
Quasispecies variant dynamics during emergence of resistance to raltegravir in HIV-1-infected patients. J Antimicrob Chemother (2009) 1.59
Genetic risk profiles identify different molecular etiologies for glioma. Clin Cancer Res (2010) 1.59
Diagnosing Treponema pallidum in secondary syphilis by PCR and immunohistochemistry. J Invest Dermatol (2007) 1.58
Dural metastases. J Neurooncol (2005) 1.56
ASPM-associated stem cell proliferation is involved in malignant progression of gliomas and constitutes an attractive therapeutic target. Cancer Cell Int (2010) 1.54
Recurrent mutations of MYD88 and TBL1XR1 in primary central nervous system lymphomas. Clin Cancer Res (2012) 1.54
CNS complications of radiotherapy and chemotherapy. Lancet (2009) 1.51
Impact of Y143 HIV-1 integrase mutations on resistance to raltegravir in vitro and in vivo. Antimicrob Agents Chemother (2009) 1.50
Whole-brain radiation therapy in breast cancer patients with brain metastases. Nat Rev Clin Oncol (2010) 1.50
Paraneoplastic neurologic syndrome in the PNS Euronetwork database: a European study from 20 centers. Arch Neurol (2010) 1.49
Dynamic history of low-grade gliomas before and after temozolomide treatment. Ann Neurol (2007) 1.48
Candidate genes on chromosome 9q33-34 involved in the progression of childhood ependymomas. J Clin Oncol (2009) 1.47
Collapsin response mediator proteins (CRMPs): involvement in nervous system development and adult neurodegenerative disorders. Mol Neurobiol (2003) 1.47
Three-tesla functional MR language mapping: comparison with direct cortical stimulation in gliomas. Neurology (2015) 1.45
Pitfalls in the diagnosis of brain tumours. Lancet Neurol (2006) 1.45
No benefit of a structured treatment interruption based on genotypic resistance in heavily pretreated HIV-infected patients. AIDS (2005) 1.45
Acute-onset chorea, dystonia, and cardiac fibroelastoma in a child: a paraneoplastic association? Mov Disord (2012) 1.44
Dramatic response to chemotherapy in oligodendroglial gliomatosis cerebri. Neurology (2003) 1.43
Oligodendrocytes are damaged by neuromyelitis optica immunoglobulin G via astrocyte injury. Brain (2010) 1.42
MGMT prognostic impact on glioblastoma is dependent on therapeutic modalities. J Neurooncol (2007) 1.42
Primary CNS lymphoma in immunocompetent patients. Oncologist (2009) 1.41
A hypermethylated phenotype is a better predictor of survival than MGMT methylation in anaplastic oligodendroglial brain tumors: a report from EORTC study 26951. Clin Cancer Res (2011) 1.40
Epileptic seizures during follow-up of patients treated for primary brain tumors. Neurology (2005) 1.38
Methylation profiling identifies 2 groups of gliomas according to their tumorigenesis. Neuro Oncol (2010) 1.38
Paraneoplastic peripheral neuropathy associated with anti-Hu antibodies. A clinical and electrophysiological study of 20 patients. Brain (2002) 1.37
NG2+/Olig2+ cells are the major cycle-related cell population of the adult human normal brain. Brain Pathol (2009) 1.37
Prognostic impact of molecular markers in a series of 220 primary glioblastomas. Cancer (2006) 1.36
Correlation between breadth of memory HIV-specific cytotoxic T cells, viral load and disease progression in HIV infection. AIDS (2002) 1.35
Temozolomide in elderly patients with newly diagnosed glioblastoma and poor performance status: an ANOCEF phase II trial. J Clin Oncol (2011) 1.34
In vivo effects of antibodies from patients with anti-NMDA receptor encephalitis: further evidence of synaptic glutamatergic dysfunction. Orphanet J Rare Dis (2010) 1.33
IDH1 and IDH2 mutations in gliomas. N Engl J Med (2009) 1.32
MGMT methylation: a marker of response to temozolomide in low-grade gliomas. Ann Neurol (2006) 1.32
Association between glioma susceptibility loci and tumour pathology defines specific molecular etiologies. Neuro Oncol (2012) 1.32
Genotypic inhibitory quotient as predictor of virological response to ritonavir-amprenavir in human immunodeficiency virus type 1 protease inhibitor-experienced patients. Antimicrob Agents Chemother (2003) 1.31
Virological and pharmacological parameters predicting the response to lopinavir-ritonavir in heavily protease inhibitor-experienced patients. Antimicrob Agents Chemother (2005) 1.30
Intracerebral administration of CpG oligonucleotide for patients with recurrent glioblastoma: a phase II study. Neuro Oncol (2010) 1.30
Level of viral load and antiretroviral resistance after 6 months of non-nucleoside reverse transcriptase inhibitor first-line treatment in HIV-1-infected children in Mali. J Antimicrob Chemother (2010) 1.29
Clinical validation of atazanavir/ritonavir genotypic resistance score in protease inhibitor-experienced patients. AIDS (2006) 1.28
Metabotropic glutamate receptor type 1 autoantibody-associated cerebellitis: a primary autoimmune disease? Arch Neurol (2010) 1.28
Clinically relevant interpretation of genotype for resistance to abacavir. AIDS (2003) 1.27
Spectrum of paraneoplastic neurologic disorders in women with breast and gynecologic cancer. Medicine (Baltimore) (2003) 1.27
Detection of HIV-1 RNA in seminal plasma samples from treated patients with undetectable HIV-1 RNA in blood plasma on a 2002-2011 survey. AIDS (2012) 1.27